Active Stocks
Tue Apr 16 2024 15:59:30
  1. Tata Steel share price
  2. 160.05 -0.53%
  1. Infosys share price
  2. 1,414.75 -3.65%
  1. NTPC share price
  2. 359.40 -0.54%
  1. State Bank Of India share price
  2. 751.90 -0.65%
  1. HDFC Bank share price
  2. 1,509.40 0.97%
Business News/ Companies / News/  Serum seeks DGCI nod for using Covovax as Covid booster dose
BackBack

Serum seeks DGCI nod for using Covovax as Covid booster dose

Covovax was approved by the DCGI for a restricted emergency use in children aged seven to 11 years in June.

India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 last year and in the 12-17 age group.Premium
India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 last year and in the 12-17 age group.

The Serum Institute of India (SII) has sought for approval for market authorisation for its COVID-19 vaccine Covovax to be administered as booster dose for those who for those aged 18 years and above and have been administered two doses of Covishield or Covaxin. 

The market authorisation application for the heterologous booster dose of Covovax has been submitted to the drugs controller general of India (DCGI) on October 17, Prakash Kumar Singh, director, government and regulatory affairs, SII, said. 

Following this, the DCGI's office raised a few queries, and Singh submitted a reply noting the current emerging situation caused by a new coronavirus variant.

Covovax was approved by the DCGI for a restricted emergency use in children aged seven to 11 years in June.

The DCGI had approved Covovax for a restricted use in emergency situations in adults on December 28, 2021 and for those in the 12-17 age group, subject to certain conditions, on March 9.

Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation.

It was granted emergency-use listing by the World Health Organization (WHO) on December 2017, 2020. In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with the SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in India and low-and-middle-income countries.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 22 Dec 2022, 07:20 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App